AbbVie Inc. ABBV

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
43/100
Developing

Ranked against 19 peers in Drug Manufacturers - General

About AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and … Full ABBV analysis →

Key strengths

  • Cash Generation Consistent Cash generation is consistent (score 0.89), indicating reliable business model.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.89).

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.25), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.10), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
44
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ABBV ranks in Drug Manufacturers - General

AbbVie Inc. ranks #14 of 20 scored companies in Drug Manufacturers - General by moat score — the top 70%. The widest moat in the group is Novo Nordisk A/S (NVO) at 74/100.

# Company Moat score Rating
10 Astrazeneca PLC AZN 52/100 Moderate
11 GSK plc GSK 52/100 Moderate
12 Grifols, S.A. GRFS 50/100 Developing
13 Eli Lilly and Company LLY 45/100 Developing
14 AbbVie Inc. ABBV 43/100 Developing
15 Pfizer, Inc. PFE 43/100 Developing
16 Organon & Co. OGN 36/100 Developing
17 Scilex Holding Company SCLX 27/100 Developing
18 Scilex Holding Company SCLXW 26/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How ABBV scores on the Corporate Default defenses

Pricing Power

Score 44 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 50 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 42 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 31 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 33 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 62 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ABBV's moat

What is AbbVie Inc.'s moat score?

AbbVie Inc. (ABBV) scores 43 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #14 of 20 scored companies in Drug Manufacturers - General, the top 70%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Scale & Market Position (62/100) and its weakest is Capital Efficiency (31/100).

How does AbbVie Inc. compare with other Drug Manufacturers - General companies?

AbbVie Inc. ranks #14 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Eli Lilly and Company (LLY) at 45 just above it and Pfizer, Inc. (PFE) at 43 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.

Why is AbbVie Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for AbbVie Inc.?

The Corporate Default template measures 6 defenses, and ABBV scores: Pricing Power (44), Cost Advantage (50), Customer Stickiness (42), Capital Efficiency (31), Resilience (33), Scale & Market Position (62). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000